SCHEMBL1999469

SCHEMBL1999469

CCn1nc(C(=O)OCC(=O)OCc2ccccc2)cc(N)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.41
TSHR P16473 4/20 0.40
ALDH1A1 P00352 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
MAPT P10636 4/20 0.39
KDM4E B2RXH2 1/20 0.39
MAOB P27338 1/20 0.39
ADORA2A P29274 1/20 0.39
RECQL P46063 1/20 0.38
MAPK1 P28482 5/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5608167 0.97 KMT2A (0.39) KMT2ATSHRALDH1A1SMN1; SMN2LMNA
SCHEMBL2001144 0.92 MAPT (0.45) KMT2ATSHRALDH1A1SMN1; SMN2LMNA
SCHEMBL1998314 0.81 SMN1; SMN2 (0.44) KMT2AALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL1994640 0.81 KDM4E (0.43) KMT2AALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL1997786 0.80 KMT2A (0.47) KMT2AALDH1A1SMN1; SMN2LMNATP53
SCHEMBL1996427 0.80 MMP9 (0.43) KMT2AALDH1A1SMN1; SMN2LMNATP53
SCHEMBL1998180 0.80 ALDH1A1 (0.53) KMT2AALDH1A1SMN1; SMN2LMNATP53
SCHEMBL1999820 0.78 ALDH1A1 (0.42) KMT2AALDH1A1MAPTKDM4EADORA2A
SCHEMBL4057924 0.78 TP53 (0.45) KMT2ASMN1; SMN2TP53MAPK1PDE4A
SCHEMBL1999815 0.78 POLB (0.41) ALDH1A1MAPTKDM4EMAOBADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960383-B2 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL SA (ES) 2011-06-14 US disclosed
EP-1758869-B1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL SA (ES) 2010-12-22 EP disclosed
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors ALMIRALL PRODESFARMA, SA (ES) 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors PDE12, PDE4A, PDE4B KMT2A 2498/4885TSHR 2798/4885ALDH1A1 457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.